Rishi is a Partner at OrbiMed, a healthcare investment firm with $18B in AUM. In addition to Charm, he serves or has served on the boards of Enliven Therapeutics, DELFI Diagnostics, Pionyr Immunotherapeutics, Verona Pharma, Turnstone Biologics, Modis Therapeutics, NeuroPace, Avitide, Dimension Therapeutics, Symbiomix Therapeutics, ChemoCentryx, and Sientra.
Rishi has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae, and ORIC Pharmaceuticals. Prior to OrbiMed, Rishi worked as a healthcare investment banker at Raymond James & Associates, a Manager of Corporate Development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz. Rishi received a J.D. from Yale Law School and an A.B. in Biochemical Sciences from Harvard College.